Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (210)	12/21/1999 3:57:00 PM
From: John Pitera	Read Replies (1) \| Respond to of 2850

Mike, Thanks for the CRA write up----CRA--gene therapy--- CRA engages in the generation, sale and support of genomic information and related software; the discovery, licensing & validation of proprietary gene products; genetic markers, genetic variablity, and related consulting and R&D services. For the 3 mos. ended 9/99, revenues totaled $8.3M, up from $3.9M. Net loss totaled $19.4M, up from $3.6M. Results reflect increased revenues due to subscriptions initiated, offset by increased R&D expenses.